Back to Market返回行情
NO
NOVN.SW Novartis AG
SIXHealthcare$114.50-2.82%OpenMarket Cap: $218.48B
As of 2026-06-01 10:46
Valuation
P/E (TTM)
20.56
PEG
—
P/B
7.18
P/S
5.00
EV/EBITDA
14.52
DCF Value
—
FCF Yield
6.0%
Div Yield
3.2%
Margins & Returns
Gross Margin
75.1%
Operating Margin
29.9%
Net Margin
24.3%
ROE
31.5%
ROA
11.3%
ROIC
14.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 2026 | $12.83B | 73.8% | $3.66B | $3.09B | $1.61 | — |
| Q4 2025 | $13.44B | 73.4% | $3.55B | $2.43B | $1.26 | — |
| Q3 2025 | $14.36B | 75.4% | $4.50B | $3.93B | $2.00 | — |
| Q2 2025 | $14.84B | 77.6% | $4.86B | $4.04B | $2.06 | — |
| Q1 2025 | $13.62B | 76.3% | $4.66B | $3.61B | $1.82 | — |
| Q4 2024 | $13.56B | 75.5% | $3.53B | $2.82B | $1.41 | — |
| Q3 2024 | $13.17B | 75.4% | $3.63B | $3.19B | $1.57 | — |
| Q2 2024 | $12.87B | 75.3% | $4.01B | $3.25B | $1.59 | — |
| Q1 2024 | $12.12B | 74.5% | $3.37B | $2.69B | $1.31 | — |
| Q4 2023 | $11.78B | 74.3% | $2.58B | $8.48B | $4.11 | — |
| Q3 2023 | $12.09B | 74.2% | $1.76B | $1.76B | $0.85 | — |
| Q2 2023 | $11.74B | 71.5% | $2.81B | $2.32B | $1.11 | — |